{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:27:38Z","timestamp":1791908858248,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.vaccine.2016.10.043","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T00:30:16Z","timestamp":1477614616000},"page":"5878-5885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The EB66\u00ae cell line as a valuable cell substrate for MVA-based vaccines production"],"prefix":"10.1016","volume":"34","author":[{"given":"Arnaud","family":"L\u00e9on","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Madeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Guianvarc\u2019h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Dureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Champion-Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hebben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Chatrenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.043_b0005","first-page":"24","article-title":"Ver\u00e4nderung von Vaccinevirus durch Dauerpassagen in H\u00fchnerembryofibroblastenkulturen","volume":"I","author":"Mayr","year":"1964","journal-title":"Zentralbl Bakteriol B"},{"key":"10.1016\/j.vaccine.2016.10.043_b0010","first-page":"375","article-title":"Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrung mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschw\u00e4chten Organismus","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol B"},{"key":"10.1016\/j.vaccine.2016.10.043_b0015","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified vaccinia Ankara: potential as an alternative smallpox vaccine","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.043_b0020","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.10.043_b0030","doi-asserted-by":"crossref","first-page":"9907","DOI":"10.1128\/JVI.00756-10","article-title":"Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice","volume":"84","author":"Meisinger-Henschel","year":"2010","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2016.10.043_b0035","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.10.043_b0040","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.10.043_b0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0050","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2012.02.016","article-title":"Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination","volume":"30","author":"Verheust","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.043_b0055","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.copbio.2004.09.001","article-title":"Modified virus Ankara as antigen delivery system: how can we best use its potential?","volume":"15","author":"Drexler","year":"2004","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0060","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.10.043_b0065","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.043_b0070","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1586\/14760584.2013.845531","article-title":"Clinical applications of attenuated MVA poxvirus strain","volume":"12","author":"Gomez","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.043_b0075","first-page":"55","article-title":"Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development","volume":"82","author":"Moss","year":"1994","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2016.10.043_b0080","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0085","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0264-410X(02)00771-5","article-title":"Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers","volume":"21","author":"Moorthy","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.043_b0090","unstructured":"European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Note for guidance on the development of vaccinia virus based vaccines against smallpox (CPMP\/1100\/02); June 2002. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003900.pdf."},{"key":"10.1016\/j.vaccine.2016.10.043_b0095","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/v6041672","article-title":"Matrix and backstage: cellular substrates for viral vaccines","volume":"6","author":"Jordan","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.10.043_b0100","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1016\/j.vaccine.2015.06.110","article-title":"Cell substrates for the production of viral vaccines","volume":"33","author":"Aubrit","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.043_b0105","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2009.05.083","article-title":"New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation","volume":"27","author":"Lohr","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.043_b0110","first-page":"419","article-title":"The avian EB66\u00ae cell line, application to vaccines, and therapeutic protein production","volume":"64","author":"Brown","year":"2010","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0115","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0264-410X(96)00072-2","article-title":"Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model","volume":"14","author":"Wyatt","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.043_b0120","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2011.06.009","article-title":"A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C","volume":"141","author":"Habersetzer","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2016.10.043_b0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2014.03.007","article-title":"Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection","volume":"147","author":"Di Bisceglie","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2016.10.043_b0130","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2016.10.043_b0135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biologicals.2010.11.005","article-title":"A chemically defined production process for highly attenuated poxviruses","volume":"39","author":"Jordan","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2016.10.043_b0140","first-page":"882","article-title":"Production of Hantaan virus from human immortalized retina cell and its immunogenicity","volume":"12","author":"Bae","year":"2002","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0145","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.10.043_b0150","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1128\/JVI.02359-10","article-title":"Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice","volume":"85","author":"Dimier","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0155","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1099\/vir.0.19016-0","article-title":"Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release","volume":"84","author":"Meiser","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10616-005-3795-y","article-title":"Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: implication for vaccine development","volume":"48","author":"Gilbert","year":"2005","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2016.10.043_b0165","unstructured":"WHO Expert Committee on Biological Standardization. Sixty-first report. WHO Technical Report Series, No. 978; 2013 Annex 3. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Available at: http:\/\/www.who.int\/biologicals\/expert_committee\/TRS_978_61st_report.pdf."},{"key":"10.1016\/j.vaccine.2016.10.043_b0170","unstructured":"ICH Topic Q5D. Quality of biotechnological products: derivation and characterization of cell substrates used for production of biotechnological\/biological products. CPMP\/ICH\/294\/95; 1998. Available at: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q5D\/Step4\/Q5D_Guideline.pdf."},{"key":"10.1016\/j.vaccine.2016.10.043_b0175","unstructured":"Food and Drug Administration. Center for Biologics Evaluation and Research. Guidance for industry. Characterization and qualification of cell substrates and other biologicals materials used in the production of viral vaccines for infectious disease indications; February 2010. Available at: http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/vaccines\/ucm202439.pdf."},{"key":"10.1016\/j.vaccine.2016.10.043_b0180","unstructured":"European Pharmacopoeia 5.0. 5.2.3. Cell substrates for the production of vaccines for human use; January 2005. Available at: http:\/\/lib.njutcm.edu.cn\/yaodian\/ep\/EP5.0\/05_general_texts\/5.2.__general_texts_on_vaccines\/5.2.3.%20Cell%20substrates%20for%20the%20production%20of%20vaccines%20for%20human%20use.pdf."},{"key":"10.1016\/j.vaccine.2016.10.043_b0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/infdis\/jiv091","article-title":"Immunogenicity and safety of an EB66 cell-culture-derived influenza A\/Indonesia\/5\/2005(H5N1) AS03-adjuvanted vaccine: a phase 1 randomized trial","volume":"212","author":"Schuind","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.043_b0190","unstructured":"European Pharmacopoeia, 9th ed.; 2016. Available at: https:\/\/www.edqm.eu\/en\/ph-eur-9th-edition."},{"key":"10.1016\/j.vaccine.2016.10.043_b0195","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1128\/JVI.75.22.11034-11055.2001","article-title":"Structure and assembly of intracellular mature vaccinia virus: isolated-particle analysis","volume":"75","author":"Griffiths","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0200","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0205","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/v2051050","article-title":"Surf and turf: mechanism of enhanced virus spread during poxvirus infection","volume":"2","author":"Condit","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.10.043_b0210","doi-asserted-by":"crossref","first-page":"E245","DOI":"10.1038\/ncb1101-e245","article-title":"High-speed mass transit for poxviruses on microtubules","volume":"3","author":"Moss","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.vaccine.2016.10.043_b0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/viro.2000.0411","article-title":"Enveloped virus is the major virus form produced during productive infection with the modified vaccinia virus Ankara strain","volume":"273","author":"Spehner","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.10.043_b0220","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","article-title":"Recombinant MVA vaccines: dispelling the myths","volume":"31","author":"Cottingham","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.043_b0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/aid.2007.0205","article-title":"Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C","volume":"24","author":"Burgers","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2016.10.043_b0230","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2007.10.033","article-title":"Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA","volume":"372","author":"Wyatt","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.10.043_b0235","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1016\/j.vaccine.2005.08.037","article-title":"Genetic stability of recombinant MVA-BN","volume":"24","author":"Timm","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.043_b0240","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1128\/JVI.00687-09","article-title":"Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection","volume":"83","author":"Wyatt","year":"2009","journal-title":"J Virol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2016.10.043_b0245","first-page":"26","article-title":"Culturing a duck ES-derived cell line in single-use bioreactors: a rapid, efficient, and cost-effective vaccine manufacturing system based on suspension culture","volume":"13","author":"Madeline","year":"2015","journal-title":"BioProcess Int"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T12:34:04Z","timestamp":1529930044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16309781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":49,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0264410X16309781"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The EB66\u00ae cell line as a valuable cell substrate for MVA-based vaccines production","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}